Early access to medicines scheme (EAMS) scientific opinion: Berotralstat in the treatment of hereditary angioedema

Berotralstat has been approved for use, prior to product licence, via the criteria stipulated in the EAMS by the MHRA for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older

Medicines and Healthcare products Regulatory Agency